This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Donepezil (Aricept)

Extensively Studied

The most-prescribed Alzheimer's drug in the world (FDA-approved 1996) — a piperidine-class reversible, highly selective AChE inhibitor…

Aliases (8)

Aricept · E2020 · donepezil hydrochloride · Aricept ODT · Aricept 23 · Memorit · Yasnal · DONEPEZIL

TYPICAL DOSE

5 mg

Daily

ROUTE

Oral (tablet)

Oral

CYCLE

none

As prescribed

STORAGE

Room temp; original container

Room temp

Overview

What is Donepezil (Aricept)?

Donepezil (Aricept) is a centrally-acting acetylcholinesterase inhibitor FDA-approved for Alzheimer's disease. It is one of the most-prescribed cognitive enhancers in clinical medicine.

Key Benefits

Modestly slows cognitive decline in mild-to-moderate Alzheimer's, may improve memory and attention in mild cognitive impairment, off-label use for vascular dementia. Some healthy-adult use for memory consolidation during learning.

Mechanism of Action

Reversibly inhibits acetylcholinesterase in the synaptic cleft, increasing acetylcholine availability at muscarinic and nicotinic receptors. CNS-selective with minimal peripheral cholinergic side effects compared to older agents.

▸Brand options7 known

AriceptE2020Aricept ODTAricept 23MemoritYasnalDONEPEZIL

StatusPrescription Rx, US (Schedule N — non-controlled), UK POM, EU Rx, Indian Schedule H

Peptide Interactions

Memantine (NMDA antagonist, FDA-approved for moderate-severe AD):

Synergistic

✅ Standard combination in moderate-severe AD; complementary mechanisms (cholinergic substrate + glutamatergic modulation). Not relevant-to-archetype.

Cerebrolysin:

Synergistic

⚠️ Some Eastern European protocols add Cerebrolysin to AChE inhibitors in AD. Not relevant-to-archetype unless a user in this archetype develops cognitive de…

Cognitive training / spaced retrieval / cardiovascular exercise:

Synergistic

✅ Behavioral cholinergic-axis support. Universally additive.

DHA / phosphatidylserine / citicoline:

Synergistic

⚠️ Theoretical complementarity (substrate + AChEI), but at clinical AChEI dose the bottleneck is no longer choline supply — synaptic ACh is already maximized…

Other AChE inhibitors (huperzine A, galantamine, rivastigmine, alpha-GPC at high chronic dose):

Avoid

❌ Cholinergic excess risk. Additive AChE inhibition + raised substrate = nausea, sweating, bradycardia, tremor, REM hyper-disinhibition. Pick one cholinergic…

Beta-blockers (propranolol, metoprolol):

Avoid

❌ Additive bradycardia. Donepezil + propranolol can produce symptomatic bradycardia and AV block. If both are needed (anxiety + cognitive support), do so und…

Anticholinergic drugs (oxybutynin, TCAs, diphenhydramine, scopolamine, first-gen antihistamines):

Avoid

❌ Pharmacodynamic antagonism — anticholinergics blunt donepezil's effect. Stupid combination.

Neuromuscular blockers (succinylcholine, vecuronium):

Avoid

⚠️ Donepezil can prolong succinylcholine action (AChE inhibition affects metabolism). Surgical relevance — disclose donepezil before anesthesia.

CYP3A4 strong inhibitors (ketoconazole, ritonavir, clarithromycin):

Avoid

⚠️ Increased donepezil exposure; consider dose reduction.

CYP3A4 strong inducers (rifampin, carbamazepine, St. John's Wort):

Avoid

⚠️ Reduced donepezil exposure; clinical effect may diminish.

CYP2D6 strong inhibitors (paroxetine, fluoxetine, bupropion):

Avoid

⚠️ Increased exposure. the user's V stack backup includes bupropion — if he were ever on donepezil + bupropion, expect higher donepezil levels.

NSAIDs (ibuprofen, naproxen):

Avoid

⚠️ Additive GI bleed risk via cholinergic gastric acid stimulation.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Onset
3-4 hr to peak plasma. Subjective effect typically minimal day 1.
Day 2-7
GI side effects dominate — nausea, loose stool, occasional vomiting, especially in first 1-2 weeks. Often dose-limiting.

Side Effects & Safety 16

Side Effects

1Nausea, vomiting, diarrhea (10-25% of users in pivotal trials at 10 mg/day). Usually first 4-6 weeks; often improves but can persist.
2Anorexia / weight loss. Modest but often clinically significant in elderly. ~3-5% loss of body weight common over 6 months. Concern for users in this archetype: 185-190 lb athlete who needs the calories — chronic anorexia is a non-trivial cost.
3Vivid dreams, nightmares, sleep disturbance. Up to 30% of users at 10 mg HS report some dream-related complaint.
4Insomnia. ~5-15% — both initiation and maintenance insomnia. Often dose-related.
5Headache. ~10% early; usually subsides.
6Muscle cramps, especially leg cramps at night. ~6-8%. Cholinergic muscle activation.
7Fatigue. Sometimes paradoxical — cholinergic over-tone in a young subject can produce mental fog rather than activation.
8Dizziness, syncope. Cholinergic + bradycardic.
9Bradycardia (asymptomatic on ECG). Vagal tone increase from cholinergic activation.
10Bradycardia (symptomatic) — light-headedness, near-syncope. Less common but clinically important.
11Mood changes: depression, irritability, agitation. ~3-5%. Sometimes severe enough to discontinue.
12Urinary frequency, incontinence. Cholinergic bladder hyperactivity.
13Hypersalivation, sweating, lacrimation (peripheral cholinergic).
14Tremor, parkinsonian features. Rare-mild; reverses on stopping.
15GI bleeding in users on NSAIDs (cholinergic stomach acid stimulation + NSAID mucosal injury).
16Rhinitis, increased respiratory secretions.

When to Stop

Severe bradycardia / heart block. Most concerning cardiac signal. Donepezil increases vagal tone; in patients with conduction abnormalities (sick sinus, AV block, on beta-blockers, on digoxin), this can produce symptomatic bradycardia, syncope, or AV block. Several case reports of pacemaker requirement after donepezil initiation. 2024-2025 pharmacovigilance signal: ongoing — FDA label warns of bradycardia and syncope; some real-world data suggest under-reported.
Sudden cardiac death. Very rare, signal exists in pharmacovigilance databases but causation is hard to establish in elderly populations with high baseline cardiac mortality. Not a real concern at population level for healthy 20yo, but mechanistically the bradycardia pathway is the same.
Syncope leading to fall / hip fracture. Major elderly concern; not relevant-to-archetype.
REM sleep behavior disorder (RBD) — case reports of donepezil-induced RBD (acting out dreams, sometimes injuriously). Mechanistically consistent with cholinergic REM disinhibition. For an Combat athlete sleeping next to a partner this is a non-trivial concern.
Seizures. Lower threshold; rare. Risk in patients with seizure history or concomitant pro-convulsant drugs.
Stevens-Johnson syndrome / TEN. Extremely rare; mentioned for completeness.
Hepatotoxicity. Rare; most cases mild transaminitis.
Severe vomiting → esophageal rupture. A handful of case reports.
Serotonin syndrome when combined with serotonergic agents (rare).
Neuroleptic malignant syndrome-like reactions. Extremely rare.
First 4-6 weeks: GI tolerance, sleep disturbance, mood. Most discontinuations happen here.
First 8-12 weeks: cardiac signal (bradycardia, syncope) — get baseline ECG if significant cardiac risk; recheck if symptoms.
First 6 months: weight, mood, REM behavior.
Indefinite: sleep architecture (REM intensity), cognitive plateau or decline (AD context), drug interactions as new meds added.